Single-Session Radiotherapy Shows Promise in Prostate Cancer Treatment

A groundbreaking radiotherapy trial suggests that prostate cancer could be effectively treated in just one session, offering hope for faster and more convenient treatment options.

The landscape of prostate cancer treatment is on the cusp of a significant transformation. A pioneering radiotherapy technique, known as stereotactic radiotherapy (SABR)is being hailed for its potential to eradicate prostate cancer in a single session. This innovative approach, which has already been introduced in some NHS centers, promises to revolutionize the way prostate cancer is managed.

Traditionally, prostate cancer treatment involves a lengthy process of radiotherapy sessionsoften requiring patients to undergo 20 sessions or more. However, the introduction of SABR has reduced this to just five sessions over a fortnight. Now, an early-stage trial conducted by the Oncology Institute of Southern Switzerland suggests that this cutting-edge treatment could be further streamlined to a single session, offering a more efficient and less burdensome option for patients.

Understanding Stereotactic Radiotherapy (SABR)

SABR is a precision treatment that utilizes high doses of radiation directed at the tumor from multiple angles. This method not only shortens the treatment duration but also minimizes the risk of tumor growth or spread while sparing healthy tissue.

The trial, which involved 43 men with localized prostate cancer across five hospitals in Europe and the United Statesreported that 92.9% of participants were free of prostate cancer after three years, based on their PSA blood test results.

The trial’s findings, published in the medical journal JAMA Oncologyindicate that single-fraction SBRT (stereotactic body radiotherapy) remains a promising approach. However, the researchers emphasize the need for further confirmation through larger cohorts and longer follow-up periods. The UK and US use different acronyms for this treatment, with the UK referring to it as SABR and the US as SBRTbut the technique remains the same.

The Impact on NHS and Patient Care

The potential reduction in treatment sessions has been described as ‘transformative’ by charities, as it allows doctors to cut waiting lists faster and saves patients the inconvenience of multiple hospital visits. Some NHS hospitals have already started using SABR for prostate cancer treatment this month, following previous UK-led clinical trials that demonstrated its effectiveness over five sessions.

NHS England has announced that all 48 centers will have the necessary machines and staff to offer SABR within three months. They will await further trial results before deciding whether to adopt the ‘one and done’ regimen. Professor Peter Johnsonnational clinical director for cancer at NHS Englandhighlighted the NHS’s commitment to transforming treatment for thousands of men with prostate cancer. He noted that the NHS is already rolling out a five-dose high-powered ‘precision’ radiotherapy to target the disease more effectively.

Expert Opinions and Future Prospects

David Jamesdirector of patient projects and influencing at Prostate Cancer Researchexpressed enthusiasm for the results, stating that anything that safely reduces the burden of treatment for men with prostate cancer is worth exploring. He emphasized the transformative potential of treating some men in a single session rather than over multiple hospital visits. However, he cautioned that larger studies and longer follow-up are needed to confirm these findings.

Simon Grievesonassistant director of research at Prostate Cancer UKechoed these sentiments, noting that recent progress has already reduced the number of sessions from twenty to five. The idea of further reducing this to a single session is an exciting prospect, making treatment much quicker and easier for men. He stressed the importance of ensuring that men receive the right treatment for their cancer and that further trials are needed to compare this shorter schedule to current practice.

The Daily Mail is campaigning for better diagnosis and treatment of prostate cancer, advocating for the introduction of a targeted screening program to end needless deaths. As research continues, the prospect of a single-session cure for prostate cancer offers hope for a brighter future in cancer treatment.